Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSSIT: Clopidogrel for prevention of systemic sclerosis in Raynaud phenomenon with SSc-related autoimmunity
2024-511005-39-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) and Raynaud disease comparing Clopidogrel (Plavix) arm with Placebo arm (2 arms). Planned start Feb 2024; status: authorised.
02
Drugs
clopidogrel
03
Conditions
systemic sclerosis (SSc)Raynaud disease
Beyond the preview
Go deeper on 2024-511005-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511005-39-00.